摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(8-nitroquinolin-4-yloxy)phenylamine | 1174997-03-5

中文名称
——
中文别名
——
英文名称
4-(8-nitroquinolin-4-yloxy)phenylamine
英文别名
4-(8-nitroquinolin-4-yl)oxyaniline
4-(8-nitroquinolin-4-yloxy)phenylamine化学式
CAS
1174997-03-5
化学式
C15H11N3O3
mdl
——
分子量
281.271
InChiKey
BSWKLQIVEREVPJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    500.0±45.0 °C(Predicted)
  • 密度:
    1.396±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    94
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
    摘要:
    STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors. (C) 2011 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2011.04.007
  • 作为产物:
    描述:
    4-氯-8-硝基喹啉对氨基苯酚potassium tert-butylate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 7.0h, 以59%的产率得到4-(8-nitroquinolin-4-yloxy)phenylamine
    参考文献:
    名称:
    对黑色素瘤细胞系具有抗增殖活性的氨基喹啉衍生物
    摘要:
    描述了一系列新的氨基喹啉衍生物1a–p的合成及其对A375人黑素瘤细胞系的抗增殖活性。大多数化合物显示出比索拉非尼(作为参考化合物)优越的抗增殖活性。其中,喹啉基氧基甲基苯基化合物1k和1l表现出强大的活性(分别为IC 50  = 0.77和0.79μM),并且对黑素瘤和成纤维细胞系具有优异的选择性。
    DOI:
    10.1016/j.bmcl.2009.05.007
点击查看最新优质反应信息

文献信息

  • AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    申请人:YOO Kyung-Ho
    公开号:US20100249182A1
    公开(公告)日:2010-09-30
    Provided are a novel aminoquinoline compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, preparation method thereof, and a pharmaceutical composition for preventing or treating cutaneous cancer, comprising the aminoquinoline compound or pharmaceutically acceptable salt thereof. Since the compound of Formula 1 exhibits excellent anti-proliferative effect on melanoma tumor cells, it is useful for preventing or treating cutaneous cancer. wherein R 1 , R 2 , and R 3 are defined in the specification.
    提供的是一种由化学式1表示的新型氨基喹啉化合物或其药用盐,以及其制备方法和用于预防或治疗皮肤癌的药物组合物,包括该氨基喹啉化合物或其药用盐。由于化合物1的表现在黑色素瘤细胞上具有出色的抗增殖效果,因此对于预防或治疗皮肤癌是有用的。其中R1、R2和R3在说明书中有定义。
  • Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same
    申请人:Korea Institute of Science and Technology
    公开号:US08049014B2
    公开(公告)日:2011-11-01
    Provided are a novel aminoquinoline compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, preparation method thereof, and a pharmaceutical composition for preventing or treating cutaneous cancer, comprising the aminoquinoline compound or pharmaceutically acceptable salt thereof. Since the compound of Formula 1 exhibits excellent anti-proliferative effect on melanoma tumor cells, it is useful for preventing or treating cutaneous cancer. wherein R1, R2, and R3 are defined in the specification.
    提供了一种新型的氨基喹啉化合物,其化学式为1或其药学上可接受的盐,以及其制备方法和制备用于预防或治疗皮肤癌的药物组合物,包括氨基喹啉化合物或其药学上可接受的盐。由于化合物1对黑色素瘤肿瘤细胞表现出出色的抗增殖效果,因此它对于预防或治疗皮肤癌非常有用。其中R1、R2和R3在说明书中有定义。
  • US8049014B2
    申请人:——
    公开号:US8049014B2
    公开(公告)日:2011-11-01
  • Aminoquinoline derivatives with antiproliferative activity against melanoma cell line
    作者:Bong Soo Nam、Hwan Kim、Chang-Hyun Oh、So Ha Lee、Seung Joo Cho、Tae Bo Sim、Jung-Mi Hah、Dong Jin Kim、Jung Hoon Choi、Kyung Ho Yoo
    DOI:10.1016/j.bmcl.2009.05.007
    日期:2009.7
    The synthesis of a novel series of aminoquinoline derivatives 1a–p and their antiproliferative activities against A375 human melanoma cell line were described. Most compounds showed superior antiproliferative activities to Sorafenib as a reference compound. Among them, quinolinyloxymethylphenyl compounds 1k and 1l exhibited potent activities (IC50 = 0.77 and 0.79 μM, respectively) and excellent selectivity
    描述了一系列新的氨基喹啉衍生物1a–p的合成及其对A375人黑素瘤细胞系的抗增殖活性。大多数化合物显示出比索拉非尼(作为参考化合物)优越的抗增殖活性。其中,喹啉基氧基甲基苯基化合物1k和1l表现出强大的活性(分别为IC 50  = 0.77和0.79μM),并且对黑素瘤和成纤维细胞系具有优异的选择性。
  • Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
    作者:Kuen-Feng Chen、Wei-Tien Tai、Jui-Wen Huang、Cheng-Yi Hsu、Wei-Lin Chen、Ann-Lii Cheng、Pei-Jer Chen、Chung-Wai Shiau
    DOI:10.1016/j.ejmech.2011.04.007
    日期:2011.7
    STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors. (C) 2011 Elsevier Masson SAS. All rights reserved.
查看更多